Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Short-Term Debt & Capital Lease Obligation

: $2,572 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Takeda Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2,572 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Takeda Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $29,822 Mil.

Takeda Pharmaceutical Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Takeda Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

8,861.87

5,450.28

203.80

1,720.34

2,540.69

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															2,757.44	2,540.69	2,948.96	1,858.98	2,571.80

Takeda Pharmaceutical Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Takeda Pharmaceutical Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.